N-Desmethyltamoxifen

N-Desmethyltamoxifen is a primary metabolite of tamoxifen, a medication used in the treatment of breast cancer. It is produced in the body by the action of the enzyme cytochrome P450 (CYP) 2D6.

Chemistry

N-Desmethyltamoxifen is a triazine derivative and is classified as a selective estrogen receptor modulator (SERM). It has a similar structure to tamoxifen, with the exception of a missing methyl group.

Pharmacology

N-Desmethyltamoxifen acts as an antagonist at estrogen receptors, blocking the effects of estrogen in the body. This action is particularly important in the treatment of estrogen receptor-positive breast cancer, where the growth of cancer cells is stimulated by estrogen.

Metabolism

N-Desmethyltamoxifen is metabolized in the liver by the enzyme CYP2D6. The activity of this enzyme can vary between individuals due to genetic differences, which can affect the levels of N-Desmethyltamoxifen in the body and therefore the effectiveness of tamoxifen treatment.

Clinical significance

The levels of N-Desmethyltamoxifen in the body can be used as a marker of tamoxifen treatment effectiveness. Lower levels may indicate that the body is not metabolizing tamoxifen effectively, which could lead to reduced treatment effectiveness.

See also

• Tamoxifen
• Cytochrome P450
• Breast cancer

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian